Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07511556 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of UX016 in GNEM
A Phase 1 study, sponsored by Ultragenyx Pharmaceutical.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07511556 is a Phase 1 study that has not yet begun recruiting, run by Ultragenyx Pharmaceutical. The registered enrollment target is 24 participants.
The verdict
NCT07511556, a Phase 1 study, has not yet begun recruiting, sponsored by Ultragenyx Pharmaceutical.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The main goal of this study is to evaluate the safety of UX016 and to evaluate the impact of UX016 on muscle strength in adults with GNE Myopathy (GNEM).
Interventions
- OTHER Placebo
- DRUG UX016
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-10 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07511556
The ClinicalTrials.gov registry entry for NCT07511556 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07511556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07511556 about?
NCT07511556 is a clinical study titled "First-in-human Study of UX016 in GNEM". The main goal of this study is to evaluate the safety of UX016 and to evaluate the impact of UX016 on muscle strength in adults with GNE Myopathy (GNEM).
What is the current status of trial NCT07511556?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-10. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07511556?
The interventions under investigation include: Placebo (OTHER), UX016 (DRUG).
Who is sponsoring clinical trial NCT07511556?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.